These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32200459)
1. Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma. Drexler R; Wagner KC; Küchler M; Feyerabend B; Kleine M; Oldhafer KJ J Cancer Res Clin Oncol; 2020 May; 146(5):1125-1137. PubMed ID: 32200459 [TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Schäfer C; Seeliger H; Bader DC; Assmann G; Buchner D; Guo Y; Ziesch A; Palagyi A; Ochs S; Laubender RP; Jung A; De Toni EN; Kirchner T; Göke B; Bruns C; Gallmeier E J Cell Mol Med; 2012 Aug; 16(8):1776-91. PubMed ID: 22004109 [TBL] [Abstract][Full Text] [Related]
3. The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer. Okuno M; Yasuda I; Adachi S; Nakashima M; Kawaguchi J; Doi S; Iwashita T; Hirose Y; Kozawa O; Yoshimi N; Shimizu M; Moriwaki H Oncotarget; 2016 Mar; 7(12):14291-9. PubMed ID: 26895107 [TBL] [Abstract][Full Text] [Related]
4. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325 [TBL] [Abstract][Full Text] [Related]
5. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer. Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932 [TBL] [Abstract][Full Text] [Related]
7. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380 [TBL] [Abstract][Full Text] [Related]
8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
9. The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. Okuno M; Adachi S; Kozawa O; Shimizu M; Yasuda I Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805817 [TBL] [Abstract][Full Text] [Related]
10. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer. Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811 [TBL] [Abstract][Full Text] [Related]
11. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050 [TBL] [Abstract][Full Text] [Related]
12. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476 [TBL] [Abstract][Full Text] [Related]
13. Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells. Tokunaga M; Baron B; Kitagawa T; Tokuda K; Kuramitsu Y Anticancer Res; 2015 Nov; 35(11):6063-7. PubMed ID: 26504030 [TBL] [Abstract][Full Text] [Related]
14. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Mori-Iwamoto S; Kuramitsu Y; Ryozawa S; Mikuria K; Fujimoto M; Maehara S; Maehara Y; Okita K; Nakamura K; Sakaida I Int J Oncol; 2007 Dec; 31(6):1345-50. PubMed ID: 17982661 [TBL] [Abstract][Full Text] [Related]
15. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187 [TBL] [Abstract][Full Text] [Related]
16. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Suenaga S; Kuramitsu Y; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K Anticancer Res; 2014 Jan; 34(1):141-6. PubMed ID: 24403454 [TBL] [Abstract][Full Text] [Related]
17. Correlation of laminin subunit alpha 3 expression in pancreatic ductal adenocarcinoma with tumor liver metastasis and survival. Xing Y; Jing X; Qing G; Jiang Y Radiol Oncol; 2024 Jun; 58(2):234-242. PubMed ID: 38452390 [TBL] [Abstract][Full Text] [Related]
18. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells. Kang D; Choi HJ; Kang S; Kim SY; Hwang YS; Je S; Han Z; Kim JH; Song JJ Cell Signal; 2015 Apr; 27(4):807-17. PubMed ID: 25615626 [TBL] [Abstract][Full Text] [Related]
19. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. Kawano M; Kaino S; Amano S; Shinoda S; Suenaga S; Sen-Yo M; Sakaida I In Vivo; 2018; 32(3):637-642. PubMed ID: 29695571 [TBL] [Abstract][Full Text] [Related]
20. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]